Biodesix Inc
NASDAQ:BDSX
| Market Cap (Intraday) | 206.12M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $2.37 |
| 50-Day MA | $1.85 |
| 200-Day MA | $1.70 |
Biodesix Inc Stock, NASDAQ:BDSX
2970 Wilderness Place, Suite 100, Boulder, Colorado 80301
United States of America
Phone: +1.303.417.0500
Number of Employees: 218
Description
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Boulder, CO.